Dorzolamide/Timolol Fixed Combination: Learning from the Past and Looking Toward the Future

Konstas, Anastasios G. P.; Schmetterer, Leopold; Katsanos, Andreas; Hutnik, Cindy; Holló, Gábor; Quaranta, Luciano; Teus, Miguel A.; Uusitalo, Hannu; Pfeiffer, Norbert; Katz, L. Jay

doi:10.1007/s12325-020-01525-5

Cited by 21 publications

(14 citation statements)

References 190 publications

(253 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…DzT-FC (fixed combination of Timolol 0.5% and Dorzolamide 2%) was the first IOP-lowering fixed combination approved by the US Food and Drug Administration (FDA) in the treatment of POAG and NTG ( Konstas et al, 2021 ). PF-DzT-FC 1 (preservative-free fixed combination of Timolol 0.5% and Dorzolamide 2%) and PF-DzT-FC 2 (preservative-free fixed combination of Timolol 0.5% and Dorzolamide 1%) have also been launched in the market in recent year.…”

Section: Topical Fixed Combination Of Two Agentsmentioning

confidence: 99%

Topical Medication Therapy for Glaucoma and Ocular Hypertension

Wang

Cao²,

Jiang³

et al. 2021

Front. Pharmacol.

View full text Add to dashboard Cite

Glaucoma is one of the most common causes of blindness, thus seriously affecting people’s health and quality of life. The topical medical therapy is as the first line treatment in the management of glaucoma since it is inexpensive, convenient, effective, and safe. This review summarizes and compares extensive clinical trials on the topical medications for the treatment of glaucoma, including topical monotherapy agents, topical fixed-combination agents, topical non-fixed combination agents, and their composition, mechanism of action, efficacy, and adverse effects, which will provide reference for optimal choice of clinical medication. Fixed-combination therapeutics offer greater efficacy, reliable security, clinical compliance, and tolerance than non-fixed combination agents and monotherapy agents, which will become a prefer option for the treatment of glaucoma. Meanwhile, we also discuss new trends in the field of new fixed combinations of medications, which may better control IOP and treat glaucoma.

show abstract

Section: Topical Fixed Combination Of Two Agentsmentioning

confidence: 99%

Topical Medication Therapy for Glaucoma and Ocular Hypertension

Wang

Cao²,

Jiang³

et al. 2021

Front. Pharmacol.

View full text Add to dashboard Cite

show abstract

“…This study compared two formulations of PF eye drops-tafluprost and dorzolamide/ timolol-with P-latanoprost eye drops, which contain the preservative BAK (0.2 mg/mL). In addition to the fact that BAK is a known cause of corneal toxicities [13,15,17,20,21], chronic, low-grade inflammation of the ocular surface associated with BAK use, which is a risk factor for an increased incidence of AEs, lower tolerability, therapy failure, increased scarring, and subsequent filtration surgery failure, can occur with the long-term use of IOP-lowering therapies [31]. Consequently, the development of PF eye drops which can avoid the toxic effects associated with preservative-containing medications, may signal the way forward for lifelong IOP-lowering therapy [31].…”

Section: Discussionmentioning

confidence: 99%

“…In addition to the fact that BAK is a known cause of corneal toxicities [13,15,17,20,21], chronic, low-grade inflammation of the ocular surface associated with BAK use, which is a risk factor for an increased incidence of AEs, lower tolerability, therapy failure, increased scarring, and subsequent filtration surgery failure, can occur with the long-term use of IOP-lowering therapies [31]. Consequently, the development of PF eye drops which can avoid the toxic effects associated with preservative-containing medications, may signal the way forward for lifelong IOP-lowering therapy [31]. According to previous in vitro and in vivo confocal microscopy studies, preservatives commonly contained in PGAs can potentially adversely affect meibomian gland function leading to further exaggeration of the risk for ocular surface dysfunction and, in that context, Guo et al recently reported that diquafosol can circumvent this effect on meibomian gland dysfunction in patients treated with preserved PGAs comparable to being treated with preservative-free PGAs [32].…”

Section: Discussionmentioning

confidence: 99%

Efficacy, Safety and Patient-Reported Outcomes with Preservative-Free (PF) Tafluprost or PF-Dorzolamide/Timolol Compared with Preserved Latanoprost: A Prospective Multicenter Study in Korean Glaucoma Patients with Ocular Surface Disease

2022

View full text Add to dashboard Cite

To compare the efficacy, patient-reported satisfaction, and safety of preservative-free (PF)-tafluprost, PF-dorzolamide/timolol and preservative-containing (P)-latanoprost in Korean glaucoma patients with ocular surface disease (OSD). In a multicenter, prospective, interventional, non-randomized, controlled 12-week trial, 107 eligible patients received PF-tafluprost (n = 37), PF-dorzolamide/timolol (n = 34), or P-latanoprost eye drops (n = 36). Outcomes included changes from baseline in OSD Index (OSDI) scores (primary endpoint), intraocular pressure (IOP), and patient-reported treatment satisfaction, and safety at 12 weeks. At 12 weeks, the mean total OSDI and subdomain (dry eye symptoms, visual-related function, environmental triggers) scores significantly improved from baseline with PF-tafluprost and PF-dorzolamide/timolol, but not with P-latanoprost. Significantly more PF-tafluprost than P-latanoprost recipients reported ‘highly improved/improved’ satisfaction (no significant difference between PF-dorzolamide/timolol and P-latanoprost). IOP changes were comparable among all three treatment groups. No new safety concerns were observed. PF-tafluprost and PF-dorzolamide/timolol showed statistically and clinically significant reductions in OSDI compared with P-latanoprost in Korean glaucoma patients with OSD.

show abstract

“…[ 22 23 24 ] A recently published review of literature suggests ample evidence with the use of dorzolamide–timolol fixed combination as initial therapy to promptly lower significantly high IOP in the presence of significant damage and particularly so in glaucoma with alarming 24-h IOP characteristics. [ 25 ] A recent study conducted by Dixit et al . [ 26 ] also showed >30% reduction in IOP with fixed combination of brinzolamide and timolol eye drops and no side effects, thereby supporting this drug as primary monotherapy in treatment of POAG.…”

Section: Discussionmentioning

confidence: 99%

Comparative study to assess efficacy and safety of brinzolamide1% and timolol0.5% fixed combination eye drops versus dorzolamide2% and timolol0.5% fixed combination eye drops in management of open-angle glaucoma

Agarwal

Tayal

Gautum

2022

Journal of Family Medicine and Primary Care

View full text Add to dashboard Cite

Aim and Objective: To compare the efficacy and safety of brinzolamide1% and timolol0.5% fixed combination eye drops versus dorzolamide2% and timolol0.5% fixed combination eye drops in the treatment of primary open-angle glaucoma Design: Prospective, randomized, comparative, interventional study Setting: Tertiary eye care centre. Material and Method: The present study was a comparative study carried out on patients visiting OPD of Ophthalmology Department and diagnosed with primary open-angle glaucoma. Group 1 (n-30 BT) received brinzolamide1% and timolol0.5% fixed combination eye drops, and Group 2 (N-30 DT) patients received dorzolamide2% and timolol0.5% fixed combination eye drops. A complete ophthalmic examination was performed, including Goldmann applanation tonometry. IOP was measured twice daily (9 AM and 4 PM). The patients were evaluated at 2, 4, 8, and 12 weeks. IOP was measured at follow-up. Side effects and tolerability of both drugs were assessed, and patient preference for drugs was noted Results: Mean reduction in morning IOP was significantly more in Group 1 than in Group 2 at 8 weeks and 12 weeks (p < 0.05). Mean reduction in evening IOP was significantly more in Group 1 than in Group 2 at all follow-ups (p < 0.05) Conclusion: Brinzolamide1% + timolol0.5% fixed drug combination is more preferred and effective in lowering IOP than dorzolamide2% + timolol0.5% fixed drug combination in patients of primary open-angle glaucoma.

show abstract

Dorzolamide/Timolol Fixed Combination: Learning from the Past and Looking Toward the Future

Cited by 21 publications

References 190 publications

Topical Medication Therapy for Glaucoma and Ocular Hypertension

Topical Medication Therapy for Glaucoma and Ocular Hypertension

Efficacy, Safety and Patient-Reported Outcomes with Preservative-Free (PF) Tafluprost or PF-Dorzolamide/Timolol Compared with Preserved Latanoprost: A Prospective Multicenter Study in Korean Glaucoma Patients with Ocular Surface Disease

Comparative study to assess efficacy and safety of brinzolamide1% and timolol0.5% fixed combination eye drops versus dorzolamide2% and timolol0.5% fixed combination eye drops in management of open-angle glaucoma

Contact Info

Product

Resources

About